{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:49:14Z","timestamp":1794667754153,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-02064-1","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T17:34:16Z","timestamp":1765647256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials"],"prefix":"10.1186","volume":"18","author":[{"given":"Lishen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinchao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"issue":"10397","key":"2064_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong KL, Stafford LK, McLaughlin SA, et al. Global, regional, and National burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet. 2023;402(10397):203\u201334.","journal-title":"Lancet"},{"issue":"9","key":"2064_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"K Rao","year":"2011","unstructured":"Rao K, Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829\u201341.","journal-title":"N Engl J Med"},{"key":"2064_CR3","doi-asserted-by":"crossref","unstructured":"Wareham NJ, Bragg F, Li L et al. Risks and Population Burden of Cardiovascular Diseases Associated with Diabetes in China: A Prospective Study of 0.5 Million Adults. PLOS Medicine, 2016. 13(7).","DOI":"10.1371\/journal.pmed.1002026"},{"key":"2064_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.672350","author":"Y Deng","year":"2021","unstructured":"Deng Y, Li N, Wu Y, et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019. Front Endocrinol. 2021. https:\/\/doi.org\/10.3389\/fendo.2021.672350.","journal-title":"Front Endocrinol"},{"issue":"5","key":"2064_CR5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/CM9.0000000000003428","volume":"138","author":"J Li","year":"2025","unstructured":"Li J, Guo K, Qiu J, et al. Epidemiological status, development trends, and risk factors of disability-adjusted life years due to diabetic kidney disease: A systematic analysis of global burden of disease study 2021. Chin Med J. 2025;138(5):568\u201378.","journal-title":"Chin Med J"},{"issue":"10431","key":"2064_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"NH Phelps","year":"2024","unstructured":"Phelps NH, Singleton RK, Zhou B, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027\u201350.","journal-title":"Lancet"},{"issue":"2","key":"2064_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/osp4.629","volume":"9","author":"S Nawaz","year":"2022","unstructured":"Nawaz S, Chinnadurai R, Al-Chalabi S, et al. Obesity and chronic kidney disease: A current review. Obes Sci Pract. 2022;9(2):61\u201374.","journal-title":"Obes Sci Pract"},{"issue":"4","key":"2064_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"issue":"7","key":"2064_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"2064_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"key":"2064_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108332","author":"S Tall Bull","year":"2022","unstructured":"Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: a novel, first-in-class, dual GIP\/GLP-1 receptor agonist. J Diabetes Complications. 2022. https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108332.","journal-title":"J Diabetes Complications"},{"issue":"5","key":"2064_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"2","key":"2064_CR13","doi-asserted-by":"publisher","first-page":"101282","DOI":"10.4239\/wjd.v16.i2.101282","volume":"16","author":"A Kamrul-Hasan","year":"2025","unstructured":"Kamrul-Hasan A, Patra S, Dutta D, et al. Renal effects and safety of Tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis. World J Diabetes. 2025;16(2):101282.","journal-title":"World J Diabetes"},{"issue":"3","key":"2064_CR14","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/dom.15410","volume":"26","author":"P Karakasis","year":"2024","unstructured":"Karakasis P, Patoulias D, Fragakis N, et al. Effect of Tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis. Diabetes Obes Metab. 2024;26(3):1090\u2013104.","journal-title":"Diabetes Obes Metab"},{"key":"2064_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2064_CR16","unstructured":"Randomized A., Placebo-Controlled, Parallel-Arm Study to Investigate the Effect of Once-Weekly Tirzepatide on Energy Expenditure and Food Intake in Obese Subjects. 2019."},{"issue":"1","key":"2064_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348.","journal-title":"JAMA"},{"issue":"6","key":"2064_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534\u201345.","journal-title":"JAMA"},{"issue":"10313","key":"2064_CR19","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","journal-title":"Lancet"},{"issue":"6","key":"2064_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10160","key":"2064_CR21","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180\u201393.","journal-title":"Lancet"},{"issue":"6","key":"2064_CR22","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","volume":"29","author":"L Gao","year":"2023","unstructured":"Gao L, Lee BW, Chawla M, et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med. 2023;29(6):1500\u201310.","journal-title":"Nat Med"},{"issue":"10402","key":"2064_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613\u201326.","journal-title":"Lancet"},{"issue":"6","key":"2064_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","volume":"10","author":"T Heise","year":"2022","unstructured":"Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous Tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418\u201329.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2064_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","volume":"10","author":"N Inagaki","year":"2022","unstructured":"Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of Tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):623\u201333.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2064_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"5","key":"2064_CR27","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2213-8587(24)00377-2","volume":"13","author":"T Kadowaki","year":"2025","unstructured":"Kadowaki T, Kiyosue A, Shingaki T, et al. Efficacy and safety of once-weekly Tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(5):384\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10300","key":"2064_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, et al. Once-weekly Tirzepatide versus once-daily insulin degludec as add-on to Metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"17","key":"2064_CR29","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/jama.2023.20294","volume":"330","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Fr\u00edas JP, Rodbard HW, et al. Tirzepatide vs insulin Lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA. 2023;330(17):1631\u201340.","journal-title":"JAMA"},{"issue":"10295","key":"2064_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist Tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"11","key":"2064_CR31","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909\u201318.","journal-title":"Nat Med"},{"issue":"7","key":"2064_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1001\/jama.2024.9217","volume":"332","author":"L Zhao","year":"2024","unstructured":"Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA. 2024;332(7):551\u201360.","journal-title":"JAMA"},{"key":"2064_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2404881.","journal-title":"N Engl J Med"},{"key":"2064_CR34","doi-asserted-by":"crossref","unstructured":"Billings L, Winne PA-O, Sharma et al. Comparison of dose escalation versus switching to Tirzepatide among people with type 2 diabetes inadequately controlled on lower doses of dulaglutide: A randomized clinical trial. 2025(1539\u20133704 (Electronic)).","DOI":"10.7326\/ANNALS-24-03849"},{"key":"2064_CR35","unstructured":"Randomized A. Phase 3, double blind trial comparing the effect of the addition of Tirzepatide versus the addition of placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes. 2025."},{"issue":"8","key":"2064_CR36","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1111\/dom.13303","volume":"20","author":"SV Arnold","year":"2018","unstructured":"Arnold SV, Kosiborod M, Wang J, et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the diabetes collaborative registry. Diabetes Obes Metab. 2018;20(8):2000\u20133.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2064_CR37","doi-asserted-by":"publisher","first-page":"102344","DOI":"10.1016\/j.cpcardiol.2023.102344","volume":"49","author":"SA Sebastian","year":"2024","unstructured":"Sebastian SA, Padda I, Johal G. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review. Curr Probl Cardiol. 2024;49(2):102344.","journal-title":"Curr Probl Cardiol"},{"issue":"4","key":"2064_CR38","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.pcad.2019.07.003","volume":"62","author":"E Braunwald","year":"2019","unstructured":"Braunwald E. Diabetes, heart failure, and renal dysfunction: the vicious circles. Prog Cardiovasc Dis. 2019;62(4):298\u2013302.","journal-title":"Prog Cardiovasc Dis"},{"issue":"21","key":"2064_CR39","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American heart association. Circulation. 2021;143(21):e984-1010.","journal-title":"Circulation"},{"issue":"1","key":"2064_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12933-020-01197-z","volume":"20","author":"T Yamada","year":"2021","unstructured":"Yamada T, Wakabayashi M, Bhalla A, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021;20(1):14.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"2064_CR41","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"2064_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"key":"2064_CR43","doi-asserted-by":"crossref","unstructured":"Recommendations on the proper use of SGLT2 inhibitors. J Diabetes Investig, 2020. 11(1): pp. 257\u201361.","DOI":"10.1111\/jdi.13160"},{"issue":"3","key":"2064_CR44","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025;31(3):951\u201362.","journal-title":"Nat Med"},{"issue":"3","key":"2064_CR45","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/cvr\/cvaf006","volume":"121","author":"R Shang","year":"2025","unstructured":"Shang R, Rodrigues B. Cardioprotective effects of a \u2018twincretin\u2019 drug Tirzepatide in heart failure following myocardial infarction. Cardiovasc Res. 2025;121(3):371\u20133.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"2064_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","volume":"12","author":"YK Cho","year":"2023","unstructured":"Cho YK, Lee YL, Jung CH. The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist. J Lipid Atheroscler. 2023;12(3):213\u201322.","journal-title":"J Lipid Atheroscler"},{"issue":"22","key":"2064_CR47","doi-asserted-by":"publisher","first-page":"e021414","DOI":"10.1161\/JAHA.121.021414","volume":"10","author":"WT Tay","year":"2021","unstructured":"Tay WT, Teng TK, Simon O, et al. Readmissions, death and its associated predictors in heart failure with preserved versus reduced ejection fraction. J Am Heart Assoc. 2021;10(22):e021414.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"2064_CR48","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"2064_CR49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13098-024-01497-4","volume":"16","author":"X Chen","year":"2024","unstructured":"Chen X, Zhang X, Xiang X, et al. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2024;16(1):251.","journal-title":"Diabetol Metab Syndr"},{"issue":"8","key":"2064_CR50","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","volume":"27","author":"GA Nichols","year":"2004","unstructured":"Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879\u201384.","journal-title":"Diabetes Care"},{"issue":"3","key":"2064_CR51","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/23969873241234238","volume":"9","author":"MI Stefanou","year":"2024","unstructured":"Stefanou MI, Theodorou A, Malhotra K, et al. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP\/GLP-1 receptor agonist Tirzepatide for type 2 diabetes: A systematic review and meta-analysis. Eur Stroke J. 2024;9(3):530\u20139.","journal-title":"Eur Stroke J"},{"issue":"11","key":"2064_CR52","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink HJL, Sattar N, Pavo I, et al. Effects of Tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11):774\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2064_CR53","doi-asserted-by":"publisher","first-page":"1416985","DOI":"10.3389\/fphar.2024.1416985","volume":"15","author":"L He","year":"2024","unstructured":"He L, Li Q, Yang Y, et al. Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. Front Pharmacol. 2024;15:1416985.","journal-title":"Front Pharmacol"},{"issue":"18","key":"2064_CR54","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","volume":"85","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Interplay of chronic kidney disease and the effects of Tirzepatide in patients with heart Failure, preserved ejection Fraction, and obesity: the SUMMIT trial. J Am Coll Cardiol. 2025;85(18):1721\u201335.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2064_CR55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336.","journal-title":"N Engl J Med"},{"key":"2064_CR56","doi-asserted-by":"publisher","first-page":"990182","DOI":"10.3389\/fcvm.2022.990182","volume":"9","author":"Y Yu","year":"2022","unstructured":"Yu Y, Hu G, Yin S, et al. Optimal dose of Tirzepatide for type 2 diabetes mellitus: a meta-analysis and trial sequential analysis. Front Cardiovasc Med. 2022;9:990182.","journal-title":"Front Cardiovasc Med"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02064-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-02064-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02064-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:03:57Z","timestamp":1767863037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-025-02064-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2064"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-02064-1","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}